Medicines Co. (MDCO) Tops Q3 EPS by 30c

Medicines Co. (NASDAQ: MDCO) reported Q3 EPS of $0.18, $0.30 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $172.4 million versus the consensus estimate of $188.3 million.

Adjusted net income was $29.3 million, or $0.47 per share, for the third quarter 2013.

For earnings history and earnings-related data on Medicines Co. (MDCO) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• 'We expect salesforce.com (CRM) to capture a meaningful share of next-gen agentic workflows': Cantor
• Wolfe remains "broadly bullish on AI semis stocks", names Top Pick